NGEN

Leidos announces strategic collaboration agreement with Microsoft

Retrieved on: 
Monday, July 31, 2023
LDOS, SOCOM 4 U.S. Navy SEALs, Integration, Microsoft, Government, Science, Public sector, Organization, United States Department of the Navy, Navy Marine Corps Intranet, SMIT, Navy, Corporation, NGEN, Artificial intelligence, AI, NYSE, NMCI, Management, Asset management, Leidos

RESTON, Va., July 31, 2023 /PRNewswire/ -- Leidos (NYSE: LDOS), a FORTUNE® 500 science and technology leader, today announced it has entered into a strategic collaboration agreement with Microsoft aimed at leveraging each company's unique strengths in the market to accelerate artificial intelligence (AI) transformation for new and existing customers in the public sector. A near-term priority for co-development is in the area of generative AI solutions to support organizational efficiency, enhanced productivity and cross domain applications.

Key Points: 
  • RESTON, Va., July 31, 2023 /PRNewswire/ -- Leidos (NYSE: LDOS), a FORTUNE® 500 science and technology leader, today announced it has entered into a strategic collaboration agreement with Microsoft aimed at leveraging each company's unique strengths in the market to accelerate artificial intelligence (AI) transformation for new and existing customers in the public sector.
  • "Leidos is continuously exploring opportunities to accelerate solving our customers' hardest problems," said Steve Hull, Executive Vice President, Enterprise and Cyber Solutions Operation, Leidos.
  • "Our collaboration with Leidos will help accelerate adoption of cloud-driven solutions to improve our customers' operations," said Angela Heise, Corporate Vice President, Worldwide Public Sector, Microsoft.
  • Leidos and Microsoft are committed to building a partner ecosystem that can identify customer challenges and work together responsibly and efficiently to solve them.

DGAP-News: Has The Controversy Around Falsified Alzheimer's Research Impacted The Path To Finding The Cure?

Retrieved on: 
Thursday, September 8, 2022
Nervous system, Advertising, National Institute, Chondroitin sulfate proteoglycan, NYSE, Observation, Foundation for the National Institutes of Health, Research, Ageing, Neuron, NASDAQ, Time, Brain, Path, Disease, PFE, Cure, NGEN, Anxiety, Agitation, Imagination, TSX, Restless, Pfizer, Amyloid, Depression, CSPG, Association, Stroke, Anger, Sigma, Donepezil, Confusion, Dementia, BIIB, Biogen, Spinal cord, Aggression, Â, Biotechnology, Patient, Pharmaceutical industry, Medical imaging, Science

Has The Controversy Around Falsified Alzheimer's Research Impacted The Path To Finding The Cure?

Key Points: 
  • Has The Controversy Around Falsified Alzheimer's Research Impacted The Path To Finding The Cure?
  • For the next 1 decades, this article would be one of the foundational resources for the amyloid hypothesis and Alzheimers research.
  • Biotech companies are researching alternative Alzheimers treatments that do not revolve around the research on amyloid deposits as the root of Alzheimers.
  • Of particular relevance to Alzheimers is research that has found an association between CSPGs and progression of the disease.

Identity and Access Management Security Provider BIO-key’s 2021 Revenue Rose 80% to $5.1M, Driven by Demand for Identity-as-a Service Cloud Solutions; Investor Call Today at 10am ET

Retrieved on: 
Tuesday, March 29, 2022
As a service, Expansion, Research, Risk, White, NIMC, Workforce, White House, Element, Federation, International, Nasdaq, GLOBE, Solution, SSO, Commerce, Annual report, Education, Engineering, History, Security (finance), MFA, Health, Industry, Single, Intelisys, Technology, United States Department of Justice, Next, NIST, Investment, IAM, Growth, Coronavirus, Program, Access management, FIDO2, NGEN, Net, COVID, Single sign-on, Partnership, Identity management, Organization, Contract, The Act, Private Securities Litigation Reform Act, Justice, Calendar, Patent, CAP, COVID-19, IBB, EMEA, Acquisition, Mobile phone, Cryptocurrency, Online shopping, Risk management, Video game, Pharmaceutical industry, Silviculture, WALL

Awarded U.S. Patent for Enabling Next-generation Continuous Biometric User Authentication , increasing BIO-keys IP Portfolio to 18 patents.

Key Points: 
  • Awarded U.S. Patent for Enabling Next-generation Continuous Biometric User Authentication , increasing BIO-keys IP Portfolio to 18 patents.
  • Swivel Secure generated approximately $3.1M in revenue and $578K in operating income in calendar 2021.
  • Currently, IDaaS revenue accounts for approximately 80% of our total software and non-recurring service revenue.
  • Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made.

Throttle Muscle is pleased to announce the addition of two industry powerhouse women to ownership group

Retrieved on: 
Thursday, March 31, 2022
Family, Muscular dystrophy, Marketing, YOU, Automotive aftermarket, Humour, Woman, Muscular Dystrophy Association, NGEN, Industry, Association, Small business, Fire, Ellie, News, Transport, Sales, Sport, Facebook

SANTA MARIA, Calif., March 31, 2022 /PRNewswire-PRWeb/ -- Throttle Muscle is pleased to announce the addition of Ellie Pentland and Ashley Konwerski to their ownership team! Ellie and Ashley join owners Tara Diaz, Veronica Apodaca and Michelle May as the dominant voices of Throttle Muscle and Muscle Blades. Most recently, both women were employees of NGEN Products where they excelled in providing excellent customer service, training and quality products.

Key Points: 
  • Throttle Muscle is pleased to announce the addition of Ellie Pentland and Ashley Konwerski to their ownership team!
  • Ellie and Ashley join owners Tara Diaz, Veronica Apodaca and Michelle May as the dominant voices of Throttle Muscle and Muscle Blades.
  • SANTA MARIA, Calif., March 31, 2022 /PRNewswire-PRWeb/ -- Throttle Muscle is pleased to announce the addition of Ellie Pentland and Ashley Konwerski to their ownership team!
  • She has worked for large industry players as well as other small business companies similar to Throttle Muscle.

NervGen Pharma Announces Intent to Conduct Groundbreaking Spinal Cord Injury Clinical Trial in Exclusive Partnership With Shirley Ryan AbilityLab, #1-Ranked Hospital in Physical Medicine & Rehabilitation

Retrieved on: 
Monday, January 10, 2022
Biotechnology, Other Health, Health, Clinical Trials, Physical Therapy, Clinical trial, Safety, Patient, NGEN, Intention, SCI, Pharmaceutical industry, NervGen, Shirley Ryan AbilityLab, NVG-291, Spinal Cord Injury, NERVGEN, SHIRLEY RYAN ABILITYLAB, NVG-291, SPINAL CORD INJURY

If these results translate to patients, NVG-291 could redefine the treatment of spinal cord injury.

Key Points: 
  • If these results translate to patients, NVG-291 could redefine the treatment of spinal cord injury.
  • Partnering with Shirley Ryan AbilityLab, a leading institution in spinal cord injury research and management of patients with spinal cord injury, is an exceptional opportunity for NervGen.
  • NervGen is excited to be working towards executing this important clinical trial for spinal cord injury patients, stated Paul Brennan, NervGens President & CEO.
  • Spinal cord injury is a devastating condition in which axons and neurons in the spinal cord are injured or transected.

Encode Ideas, L.P. Announces the Initiation of Research Coverage on NervGen Pharma Corp.

Retrieved on: 
Monday, September 13, 2021
Alzheimer's disease, Multiple sclerosis, Remyelination, Patient, Regeneration, Research, Neuroregeneration, NGEN, Sigma, Communication, Disclosure, Nerve Damage, Awareness, Pharmaceutical industry

Dover, Delaware--(Newsfile Corp. - September 13, 2021) - Encode Ideas, L.P. Initiates Research on NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF).

Key Points: 
  • Dover, Delaware--(Newsfile Corp. - September 13, 2021) - Encode Ideas, L.P. Initiates Research on NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF).
  • Encode Ideas, L.P., a healthcare focused research firm, announced today it is initiating coverage on NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF).
  • Encode Ideas, L.P. is a healthcare focused research firm, founded in 2019, providing institutional quality research and investment ideas.
  • Encode Ideas, L.P. has been retained by NervGen, Inc. to provide investor awareness and research coverage.